Galderma Group N
Galderma Group N Fundamental Analysis
Galderma Group N (GALD.SW) shows moderate financial fundamentals with a PE ratio of 73.78, profit margin of 11.64%, and ROE of 6.33%. The company generates $4.3B in annual revenue with strong year-over-year growth of 21.05%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze GALD.SW's fundamental strength across five key dimensions:
Efficiency Score
WeakGALD.SW struggles to generate sufficient returns from assets.
Valuation Score
ModerateGALD.SW shows balanced valuation metrics.
Growth Score
ModerateGALD.SW shows steady but slowing expansion.
Financial Health Score
ExcellentGALD.SW maintains a strong and stable balance sheet.
Profitability Score
WeakGALD.SW struggles to sustain strong margins.
Key Financial Metrics
Is GALD.SW Expensive or Cheap?
P/E Ratio
GALD.SW trades at 73.78 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, GALD.SW's PEG of 0.74 indicates potential undervaluation.
Price to Book
The market values Galderma Group N at 4.55 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 39.33 times EBITDA. This signals the market has high growth expectations.
How Well Does GALD.SW Make Money?
Net Profit Margin
For every $100 in sales, Galderma Group N keeps $11.64 as profit after all expenses.
Operating Margin
Core operations generate 14.66 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.33 in profit for every $100 of shareholder equity.
ROA
Galderma Group N generates $3.75 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Galderma Group N produces operating cash flow of $938.63M, showing steady but balanced cash generation.
Free Cash Flow
Galderma Group N generates strong free cash flow of $849.13M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $3.62 in free cash annually.
FCF Yield
GALD.SW converts 2.34% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
73.78
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.74
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.50
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.34
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.19
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How GALD.SW Stacks Against Its Sector Peers
| Metric | GALD.SW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 73.78 | 22.36 | Worse (Expensive) |
| ROE | 6.33% | 1238.00% | Weak |
| Net Margin | 11.64% | -5096.00% (disorted) | Strong |
| Debt/Equity | 0.34 | 1.23 | Strong (Low Leverage) |
| Current Ratio | 1.19 | 2.47 | Neutral |
| ROA | 3.75% | -191998.00% (disorted) | Weak |
GALD.SW outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Galderma Group N's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
42.16%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthEPS CAGR
263.78%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthFCF CAGR
172.80%
Industry Style: Defensive, Dividend, Low Volatility
High Growth